Literature DB >> 2073874

Determinants of estimated insulin resistance and beta-cell function in Indian, Creole and Chinese Mauritians. The Mauritius NCD Study Group.

G K Dowse1, H Qin, V R Collins, P Z Zimmet, K G Alberti, H Gareeboo.   

Abstract

Associations with insulin resistance and islet beta-cell function have been studied cross-sectionally in a population-based sample of 4278 Mauritians comprising Asian Indian, Creole and Chinese subjects. Insulin resistance and beta-cell function were estimated by a computer solved model based on fasting plasma glucose and insulin concentrations. Insulin resistance increased with declining glucose tolerance, whereas beta-cell function was highest in subjects with impaired glucose tolerance (IGT) and lowest in those with non-insulin-dependent diabetes mellitus (NIDDM). Indian subjects had the highest beta-cell function, while ethnic differences in insulin sensitivity were less marked. This may indicate that deranged beta-cell function rather than insulin resistance is the primary determinant of hyperinsulinaemia and glucose intolerance in Asian Indians. beta-Cell function declined with age more sharply than did insulin sensitivity, suggesting that the age-related decline in glucose tolerance is primarily related to loss of beta-cell function. Body mass index, waist/hip ratio, physical inactivity and female sex were independently associated with insulin resistance and beta-cell function. Subjects with a family history of diabetes had increased insulin resistance, irrespective of glucose tolerance. This or similar models may have application in longitudinal population-based studies which seek to determine the relative contributions of insulin resistance and beta-cell function to the aetio-pathogenesis of NIDDM.

Entities:  

Mesh:

Year:  1990        PMID: 2073874     DOI: 10.1016/0168-8227(90)90070-a

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  7 in total

1.  Determinants of normoglycemia and contribution to cardiovascular risk factors in a Chinese population: the Hong Kong Cardiovascular Risk Factor Study.

Authors:  G Neil Thomas; S M McGhee; C M Schooling; S Y Ho; K S L Lam; E D Janus; T H Lam
Journal:  J Endocrinol Invest       Date:  2006-06       Impact factor: 4.256

Review 2.  Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in South Asians: a Unique Population with a Growing Challenge.

Authors:  Afreen I Shariff; Nitya Kumar; William S Yancy; Leonor Corsino
Journal:  Curr Diab Rep       Date:  2020-01-30       Impact factor: 4.810

3.  Body mass index, waist circumference, waist-hip ratio, and glucose intolerance in Chinese and Europid adults in Newcastle, UK.

Authors:  N Unwin; J Harland; M White; R Bhopal; P Winocour; P Stephenson; W Watson; C Turner; K G Alberti
Journal:  J Epidemiol Community Health       Date:  1997-04       Impact factor: 3.710

4.  Severity of ultrasonographic liver steatosis and metabolic syndrome in Korean men and women.

Authors:  Hyeon-Chang Kim; Sung-Hee Choi; Hae-Won Shin; Jae-Youn Cheong; Kwan-Woo Lee; Hyun-Chul Lee; Kap-Bum Huh; Dae-Jung Kim
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

5.  Study of beta-cell function (by HOMA model) in metabolic syndrome.

Authors:  M K Garg; M K Dutta; Namita Mahalle
Journal:  Indian J Endocrinol Metab       Date:  2011-07

6.  Evidence of reduced β-cell function in Asian Indians with mild dysglycemia.

Authors:  Lisa R Staimez; Mary Beth Weber; Harish Ranjani; Mohammed K Ali; Justin B Echouffo-Tcheugui; Lawrence S Phillips; Viswanathan Mohan; K M Venkat Narayan
Journal:  Diabetes Care       Date:  2013-04-17       Impact factor: 19.112

7.  Understanding the high prevalence of diabetes in U.S. south Asians compared with four racial/ethnic groups: the MASALA and MESA studies.

Authors:  Alka M Kanaya; David Herrington; Eric Vittinghoff; Susan K Ewing; Kiang Liu; Michael J Blaha; Swapna S Dave; Fareeha Qureshi; Namratha R Kandula
Journal:  Diabetes Care       Date:  2014-04-04       Impact factor: 19.112

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.